June 22, 2020 / 10:35 PM / 2 months ago

BRIEF-Adamis Pharmaceuticals Says FDA Indicated Co's Resubmitted NDA For Zimhi As Class 2 Response To Agency's CRL

June 22 (Reuters) - Adamis Pharmaceuticals Corp:

* ADAMIS PHARMACEUTICALS - FDA HAS INDICATED THAT IT CONSIDERS CO’S RESUBMITTED NDA FOR FOR ZIMHI AS A COMPLETE, CLASS 2 RESPONSE TO FDA’S CRL

* ADAMIS PHARMACEUTICALS - FDA HAS PROVIDED A USER FEE GOAL DATE UNDER PDUFA FOR A RESPONSE BY FDA BY NOVEMBER 15 ON RESUBMITTED NDA Source text: (bit.ly/2AXUZV6) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below